MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Xencor, Inc.

< Previous 1 2 Next >
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Second Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports First Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Appoints Todd Simpson to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces Upcoming Change to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces Proposed Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Second Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports First Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Appoints Bart Cornelissen as Chief Financial Officer
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Third Quarter 2023 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
From Xencor, Inc.
Via Business Wire
Tickers XNCR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story